CRL vs. DHR: A Head-to-Head Stock Comparison
Updated onHere’s a clear look at CRL and DHR, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.
Company Profile
| Symbol | CRL | DHR |
|---|---|---|
| Company Name | Charles River Laboratories International, Inc. | Danaher Corporation |
| Country | United States | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry | Life Sciences Tools & Services | Life Sciences Tools & Services |
| Market Capitalization | 8.54 billion USD | 146.76 billion USD |
| Exchange | NYSE | NYSE |
| Listing Date | June 23, 2000 | December 29, 1978 |
| Security Type | Common Stock | Common Stock |
Historical Performance
This chart compares the performance of CRL and DHR by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.
Historical Performance at a Glance
| Symbol | CRL | DHR |
|---|---|---|
| 5-Day Price Return | -1.08% | -2.55% |
| 13-Week Price Return | 9.12% | 1.99% |
| 26-Week Price Return | 23.05% | 3.57% |
| 52-Week Price Return | -8.32% | -23.75% |
| Month-to-Date Return | 10.87% | 3.38% |
| Year-to-Date Return | -6.03% | -10.71% |
| 10-Day Avg. Volume | 1.02M | 6.06M |
| 3-Month Avg. Volume | 0.90M | 4.11M |
| 3-Month Volatility | 46.61% | 33.54% |
| Beta | 1.63 | 0.90 |
Profitability
Return on Equity (TTM)
CRL
-2.01%
Life Sciences Tools & Services Industry
- Max
- 19.96%
- Q3
- 11.51%
- Median
- 6.47%
- Q1
- 3.86%
- Min
- -6.95%
CRL has a negative Return on Equity of -2.01%. This indicates the company is generating a loss for its shareholders, which can be a result of unprofitability or negative shareholder equity and is often a sign of financial distress.
DHR
6.69%
Life Sciences Tools & Services Industry
- Max
- 19.96%
- Q3
- 11.51%
- Median
- 6.47%
- Q1
- 3.86%
- Min
- -6.95%
DHR’s Return on Equity of 6.69% is on par with the norm for the Life Sciences Tools & Services industry, indicating its profitability relative to shareholder equity is typical for the sector.
Net Profit Margin (TTM)
CRL
-1.72%
Life Sciences Tools & Services Industry
- Max
- 32.18%
- Q3
- 18.30%
- Median
- 10.19%
- Q1
- 4.20%
- Min
- -2.05%
CRL has a negative Net Profit Margin of -1.72%, indicating the company is operating at a net loss as its expenses exceeded its revenues.
DHR
14.21%
Life Sciences Tools & Services Industry
- Max
- 32.18%
- Q3
- 18.30%
- Median
- 10.19%
- Q1
- 4.20%
- Min
- -2.05%
DHR’s Net Profit Margin of 14.21% is aligned with the median group of its peers in the Life Sciences Tools & Services industry. This indicates its ability to convert revenue into profit is typical for the sector.
Operating Profit Margin (TTM)
CRL
3.09%
Life Sciences Tools & Services Industry
- Max
- 38.39%
- Q3
- 21.40%
- Median
- 13.57%
- Q1
- 8.38%
- Min
- -3.51%
CRL’s Operating Profit Margin of 3.09% is in the lower quartile for the Life Sciences Tools & Services industry. This indicates weaker profitability from core operations, which may stem from inefficiencies or competitive pressures on pricing.
DHR
18.43%
Life Sciences Tools & Services Industry
- Max
- 38.39%
- Q3
- 21.40%
- Median
- 13.57%
- Q1
- 8.38%
- Min
- -3.51%
DHR’s Operating Profit Margin of 18.43% is around the midpoint for the Life Sciences Tools & Services industry, indicating that its efficiency in managing core business operations is typical for the sector.
Profitability at a Glance
| Symbol | CRL | DHR |
|---|---|---|
| Return on Equity (TTM) | -2.01% | 6.69% |
| Return on Assets (TTM) | -0.90% | 4.28% |
| Net Profit Margin (TTM) | -1.72% | 14.21% |
| Operating Profit Margin (TTM) | 3.09% | 18.43% |
| Gross Profit Margin (TTM) | 35.03% | 59.72% |
Financial Strength
Current Ratio (MRQ)
CRL
1.36
Life Sciences Tools & Services Industry
- Max
- 3.46
- Q3
- 2.78
- Median
- 1.91
- Q1
- 1.53
- Min
- 0.43
CRL’s Current Ratio of 1.36 falls into the lower quartile for the Life Sciences Tools & Services industry. This indicates a tighter liquidity situation and a more constrained capacity to handle short-term debt than many of its competitors.
DHR
1.62
Life Sciences Tools & Services Industry
- Max
- 3.46
- Q3
- 2.78
- Median
- 1.91
- Q1
- 1.53
- Min
- 0.43
DHR’s Current Ratio of 1.62 aligns with the median group of the Life Sciences Tools & Services industry, indicating that its short-term liquidity is in line with its sector peers.
Debt-to-Equity Ratio (MRQ)
CRL
0.70
Life Sciences Tools & Services Industry
- Max
- 1.35
- Q3
- 0.74
- Median
- 0.41
- Q1
- 0.18
- Min
- 0.00
CRL’s Debt-to-Equity Ratio of 0.70 is typical for the Life Sciences Tools & Services industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.
DHR
0.33
Life Sciences Tools & Services Industry
- Max
- 1.35
- Q3
- 0.74
- Median
- 0.41
- Q1
- 0.18
- Min
- 0.00
DHR’s Debt-to-Equity Ratio of 0.33 is typical for the Life Sciences Tools & Services industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.
Interest Coverage Ratio (TTM)
CRL
1.71
Life Sciences Tools & Services Industry
- Max
- 45.00
- Q3
- 27.84
- Median
- 7.16
- Q1
- 2.12
- Min
- -14.08
In the lower quartile for the Life Sciences Tools & Services industry, CRL’s Interest Coverage Ratio of 1.71 indicates a tighter cushion for servicing debt, suggesting less financial flexibility than many of its competitors.
DHR
22.31
Life Sciences Tools & Services Industry
- Max
- 45.00
- Q3
- 27.84
- Median
- 7.16
- Q1
- 2.12
- Min
- -14.08
DHR’s Interest Coverage Ratio of 22.31 is positioned comfortably within the norm for the Life Sciences Tools & Services industry, indicating a standard and healthy capacity to cover its interest payments.
Financial Strength at a Glance
| Symbol | CRL | DHR |
|---|---|---|
| Current Ratio (MRQ) | 1.36 | 1.62 |
| Quick Ratio (MRQ) | 0.96 | 1.10 |
| Debt-to-Equity Ratio (MRQ) | 0.70 | 0.33 |
| Interest Coverage Ratio (TTM) | 1.71 | 22.31 |
Growth
Revenue Growth
EPS Growth
Dividend
Dividend Yield (TTM)
CRL
0.00%
Life Sciences Tools & Services Industry
- Max
- 1.41%
- Q3
- 0.65%
- Median
- 0.35%
- Q1
- 0.00%
- Min
- 0.00%
CRL currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.
DHR
0.55%
Life Sciences Tools & Services Industry
- Max
- 1.41%
- Q3
- 0.65%
- Median
- 0.35%
- Q1
- 0.00%
- Min
- 0.00%
DHR’s Dividend Yield of 0.55% is consistent with its peers in the Life Sciences Tools & Services industry, providing a dividend return that is standard for its sector.
Dividend Payout Ratio (TTM)
CRL
0.00%
Life Sciences Tools & Services Industry
- Max
- 113.14%
- Q3
- 61.34%
- Median
- 17.74%
- Q1
- 0.00%
- Min
- 0.00%
CRL has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.
DHR
23.85%
Life Sciences Tools & Services Industry
- Max
- 113.14%
- Q3
- 61.34%
- Median
- 17.74%
- Q1
- 0.00%
- Min
- 0.00%
DHR’s Dividend Payout Ratio of 23.85% is within the typical range for the Life Sciences Tools & Services industry, suggesting a balanced approach between shareholder payouts and company reinvestment.
Dividend at a Glance
| Symbol | CRL | DHR |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 0.55% |
| Dividend Payout Ratio (TTM) | 0.00% | 23.85% |
Valuation
Price-to-Earnings Ratio (TTM)
CRL
--
Life Sciences Tools & Services Industry
- Max
- 75.35
- Q3
- 51.00
- Median
- 32.93
- Q1
- 25.27
- Min
- 1.43
P/E Ratio data for CRL is currently unavailable.
DHR
43.45
Life Sciences Tools & Services Industry
- Max
- 75.35
- Q3
- 51.00
- Median
- 32.93
- Q1
- 25.27
- Min
- 1.43
DHR’s P/E Ratio of 43.45 is within the middle range for the Life Sciences Tools & Services industry. This suggests its valuation is in line with the sector average, representing neither a significant premium nor a discount compared to its peers.
Price-to-Sales Ratio (TTM)
CRL
2.12
Life Sciences Tools & Services Industry
- Max
- 10.49
- Q3
- 6.43
- Median
- 4.66
- Q1
- 2.88
- Min
- 1.08
In the lower quartile for the Life Sciences Tools & Services industry, CRL’s P/S Ratio of 2.12 indicates its revenue is valued more conservatively than most of its peers. This could present a compelling opportunity if the market has overlooked its sales-generating capabilities.
DHR
6.18
Life Sciences Tools & Services Industry
- Max
- 10.49
- Q3
- 6.43
- Median
- 4.66
- Q1
- 2.88
- Min
- 1.08
DHR’s P/S Ratio of 6.18 aligns with the market consensus for the Life Sciences Tools & Services industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.
Price-to-Book Ratio (MRQ)
CRL
2.22
Life Sciences Tools & Services Industry
- Max
- 6.69
- Q3
- 5.00
- Median
- 3.46
- Q1
- 2.38
- Min
- 0.93
CRL’s P/B Ratio of 2.22 is in the lower quartile for the Life Sciences Tools & Services industry. From a value investing perspective, this is favorable, as it suggests the stock is trading at a discount to its net asset value and may offer a greater margin of safety.
DHR
2.72
Life Sciences Tools & Services Industry
- Max
- 6.69
- Q3
- 5.00
- Median
- 3.46
- Q1
- 2.38
- Min
- 0.93
DHR’s P/B Ratio of 2.72 is within the conventional range for the Life Sciences Tools & Services industry. This shows a balanced market view, where the stock’s price is neither at a significant premium nor a discount to the book value of its peers.
Valuation at a Glance
| Symbol | CRL | DHR |
|---|---|---|
| Price-to-Earnings Ratio (TTM) | -- | 43.45 |
| Price-to-Sales Ratio (TTM) | 2.12 | 6.18 |
| Price-to-Book Ratio (MRQ) | 2.22 | 2.72 |
| Price-to-Free Cash Flow Ratio (TTM) | 14.76 | 30.50 |